Purpose: The impact of a new type of positron emission tomography with semiconductor detectors (New PET) on an 18 F-fluoromisonidazole (FMISO)-guided intensity-modulated radiation therapy (IMRT) plan was investigated by comparing the plan with the use of a state-of-the-art PET/computed tomography system (PET/CT) in nasopharyngeal cancer (NPC) patients. Methods and Materials: Twenty-four patients with non-NPC malignant tumors (control group) and 16 patients with NPC were subjected to FMISO-PET. The threshold of the tumor-to-muscle (T/M) ratio in each PET scan was calculated. The hypoxic volume within the gross tumor volume was determined using each PET (NewPETGTVh and PET/CTGTVh, respectively). Dose-escalation IMRT plans prescribing 84Gy to each GTVh were carried out.
Introduction
Hypoxia is well known as an important factor relating to radioresistance (1) . In head and neck cancers, hypoxia has been shown to be associated with poor outcome (2) . A recent simulation study showed that dose escalation to the hypoxic region would contribute to the tumor control probability (3) . The development of a dose escalation technique using intensity-modulated radiation therapy (IMRT) or proton beam therapy is expected for use in treating patients with head and neck cancers, including nasopharyngeal cancer (NPC) (4, 5) . Direct measurements using the Eppendorf electrode have been suggested as the gold standard for hypoxic measurement, but it is an invasive examination that is restricted to accessible tumors (6) . A non-invasive approach to measuring the hypoxic region using positron emission tomography (PET) imaging has been developed and examined in previous studies (7) . 18 F-fluoromisonidazole (FMISO) is one of the hypoxia tracers. Its binding to the molecules in viable hypoxic cells is known to be proportional to the level of hypoxia (8) .
PET using FMISO (FMISO-PET) has been expected to be usable for mapping of the hypoxic region in head and neck cancers (9) . There have been several studies about the usefulness of FMISO-PET in the treatment planning for dose escalation in IMRT of head and neck cancers (10) (11) (12) .
The hypoxic region is likely to be small, and thus high spatial resolution is necessary for planning. We have shown that a prototype of a PET system with semiconductor detectors (New PET) has a spatial resolution of 2.3 mm, which is better than that of the conventional high-resolution whole-body PET system with bismuth germanium oxide (BGO) scintillation detectors (13) . New PET was shown to be useful for delineating the uptake of NPC because of its sharper edge at the tumor boundary in 18 F-fluoro-deoxy-glucose (FDG) -PET images (14) .
In this study, we established the threshold of FMISO normal uptake using New PET and a state-of-the-art whole-body PET-computed tomography (PET-CT) system with lutetium oxyorthosilicate (LSO) scintillation detectors and extended field of view (FOV) (TruePoint Biograph 64 with True V and high-resolution option, Asahi-Siemens, Tokyo, Japan) (PET/CT) and compared the hypoxic volumes visualized by New PET and PET/CT. We performed IMRT simulation planning for the dose escalation to the hypoxic region in NPC and compared the difference in dose volume histogram (DVH) between the plan using New PET and the plan using PET/CT. We also evaluated the predictive value of FMISO uptake before chemoradiotherapy for local control in patients with NPC.
Materials and methods

Patient characteristics
Our Institutional Review Board approved the protocol for this study in 2007. Between April 2008 and March 2011, 40 newly diagnosed head and neck cancer and brain tumor patients were subjected to FMISO-PET. The process used to select study patients is shown in a flowchart in Appendix 1. Sixteen patients among them had NPC (NPC group) and received FMISO-PET before any treatment. These patients received standard treatment, and were followed by radiation oncologists and oto-laryngologists in our hospital periodically. The status of local control and survival were investigated in this study. All patients in the NPC group received New PET, and twelve patients among them received both New PET and PET/CT.
Twenty-four patients with other tumors (10 brain tumors, 9 oral cancers, 4 thyroid cancers, and 1 laryngeal cancer) were defined as the control group in this study. The patients in the control group were examined with CT and magnetic resonance imaging 
FMISO-PET scans
Details of the New PET system were described previously (13) (14) (15) . In brief, the New PET system is equipped with small semiconductor detectors and a depth of interaction (DOI) system to obtain sufficient sensitivity and a higher spatial resolution.
FMISO-PET was performed with the New PET and with PET/CT. About 400 MBq of 18 F-FMISO was injected intravenously 4 hours before scanning. Details of the performances of these two scanners are listed in Appendix 2. In the patients who were subjected to both types of PET scan, the scan order was randomly determined and the scans were performed sequentially. We used dedicated fixation during PET scanning.
Threshold of the nasopharynx-to-muscle (N/M) ratio and the tumor-to-muscle (T/M) ratio FMISO-PET images were registered to image analysis software (VOX-BASE, J-MAC SYSTEM, Sapporo). In the control group, the max value of standardized uptake value The dose-escalation IMRT simulation planning targeting the hypoxic volume Ten NPC patients received both types of FMISO-PET examination and had abnormally high FMISO uptake. The dose-escalation IMRT simulation plans targeting the hypoxic volume were generated for these 10 patients. Pinnacle3 was used to make IMRT simulation plans.
The clinical target volume 1 (CTV1) was defined as the volume containing the GTV and any microscopic disease at risk. CTV 2 and CTV 3 were at high-risk and low-risk volume, respectively. A margin of 3 mm was added to each CTV and defined as the planning target volume (PTV1, PTV2, and PTV3, respectively). The prescription dose to the PTVs and the dose constraints to the organ at risk (OAR) are shown in Table 1 .
Eighty-four Gy was prescribed to the D95 of each GTVh in this simulation study.
Hypoxia-based IMRT dose escalation plans were generated for 10 NPC patients who underwent standard-dose IMRT for their disease. We did not add the margin to expand the GTVh to the PTVh, in agreement with the procedure followed by Chao et al. (7) and 
Clinical Relevance in the NPC group
Thirteen of the 16 patients in the NPC group experienced abnormally high uptake of FMISO ( Table 2) .
Twelve patients in the NPC group received both types of PET examination, and the judgments regarding whether they had abnormally high uptake were fully consistent.
Ten of the twelve patients receiving both types of PET examination had abnormally high uptake. The data for these ten patients were the materials used for the comparison of New PET and PET/CT for simulation planning using FMISO-PET. All of the NPC patients received standard treatment with standard-dose radiation therapy (66-70Gy).
Ten patients in the NPC group received radical treatment and were followed for more than one year with a median follow-up period of 23.1 months, ranging from 14.8 to 30.8 months ( Table 3 ). Three patients experienced local relapse at 9, 11, and 12 months after the first examination in our department. One patient died as a result of NPC at 30.8 months. All patients who experienced local failure had high uptake in FMISO before treatment. No patients who showed normal uptake of FMISO-PET experienced local relapse.
The SUVmax and the volume of NewPETGTVh and PET/CTGTVh
In the ten NPC patients receiving both types of PET examination and having abnormal uptake, the mean of SUVmax in NewPETGTVh was 2.55 ± 0.71 and the mean of The mean volume of NewPETGTVh and PET/CTGTVh was 1.5 ± 1.6 cc and 4.7 ± 4.6 cc, respectively (P=0.0020) ( Figure 1 ). The GTVh was smaller with New PET for all 10 patients, irrespective of the order of the examinations. Figure 2 shows an example of both FMISO-PET images for one NPC patient. The mean fraction of NewPETGTVh was 0.04 ± 0.04 of total GTV, and that of PET/CTGTVh was 0.14 ± 0.12 (P=0.0020).
Dose-escalation IMRT simulation planning
DVH of the GTVh, PTV, and OAR are shown in Table 4 . Dose escalation was possible in all 10 patients receiving both types of PET examination using NewPETGTVh in IMRT plans, maintaining dose constraints for OAR. However, it was not possible in one patient using PET/CTGTVh in the IMRT plan, because the threshold dose to the brainstem exceeded the dose constraint. The percentage of the volume receiving ≥ 80.5Gy (V80.5Gy) of PTV (p=0.0391), V84Gy of PTV (p=0.0137), mean dose of right parotid gland (p=0.0488), V30Gy of right parotid gland (p=0.0156), V30Gy of left parotid gland (p=0.0159), and the maximum dose to the brainstem (p=0.0273) were significantly lower using NewPETGTVh than PET/CTGTVh in the IMRT plan.
Discussion
Hypoxic imaging has been developed in recent years, and FMISO, Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM), and 18 F-fluoroazomycin arabinoside (FAZA) have been investigated as hypoxic tracers (9) . Among them, FMISO has been studied with the most extensive clinical experience. However, mainly because of the limited contrast between tumor and normal tissue, there has been skepticism about the usage of FMISO as the standard in pre-treatment examination as well as for image guidance in radiotherapy planning (7) . If the resolution of PET scanners can be improved, the advantage of FMISO-PET, which has a large pre-clinical and clinical experience, would be reappraised.
We scanned the images at 4 hours after FMISO injection. Thorwarth et al. reported that blood pooling remained at 2 hours after FMISO injection, and good contrast was obtained at 4 hours after injection (16) . Our FMISO study adopted 4 hours of delay before scanning and also showed good contrast (17) .
We used the T/M ratio to evaluate FMISO uptake, because the T/M ratio was shown to correlate with the degree of hypoxia directly measured using an Eppendorf electrode The present study showed that local relapse was observed only in NPC patients with a high uptake of FMISO. This may imply that higher uptake of FMISO before radiotherapy is related to radioresistance in patients with NPC, although the number of patients in the present study was too small to allow for such a conclusion. On the other hand, Lee et al. have reported that the effects of pretreatment FMISO uptake in patients with oropharyngeal cancers could not be assessed because the population they examined was too sensitive to chemoradiotherapy and only one relapse was observed in their series (19) . Their findings do not contradict our findings and suggest the importance of selecting the disease to be examined in future studies. Reducing the entire dose of PTV while maintaining the dose gradient with a high dose to the hypoxic volume could be one strategy for dose-optimization focused on hypoxia.
The hypoxic volume defined by the New PET was smaller than defined by PET/CT. The spatial resolution after reconstruction and energy resolution of New PET was higher than that of PET/CT. On the other hand, the sensitivity per unit of time, defined as the detecting counts per second, of PET/CT was 1.8 times higher than that of the New PET. Sensitivity is an important factor in the study of low-uptake radiopharmaceuticals such as FMISO. To compensate for the relatively low sensitivity per unit of time of the New PET, we extended the emission scan time to 30 minutes, which was 3 times longer than that of PET/CT. As a result, the total counts in the New PET were comparable to those in PET/CT, and they were sufficient for the analysis. The difference in the GTVh may have been due to the difference of the scatter fraction and spatial resolution.
For head and neck cancers containing intra-tumoral hypoxia, the usefulness of dose-escalation using hypoxic imaging has been investigated. Popple et al. reported that a modest boost dose (120%-150% of the primary dose) to the hypoxic subvolume increases tumor control probability using a Monte Carlo model (3) . In the present study, we performed FMISO PET-guided IMRT simulations in 10 NPC patients. This is the first study that demonstrated the effect of the difference in PET scanners on dose escalation IMRT plans. The dose to OAR was significantly lower in the IMRT plan using New PET compared to the PET/CT. The reason is simply that the NewPETGTVh was smaller than PET/CTGTVh. Because a lower dose can be delivered to OAR and better quality of life can result, the effort to develop an accurate PET scanner is important for the innovation of radiation therapy.
The shortcoming of this study is the small number of patients included, and the absence of laboratory investigation or phantom study data. Although the local failure rate in this study seems relatively high, we could not draw any definite conclusion about the reason for this rate because of the small number of patients in this study. However, our results indicated the potential usefulness of FMISO-PET in radiation therapy and the need for caution when operating different PET scanners, such as in a multicenter clinical trial.
Conclusion
In conclusion, the difference in PET scanner used for examination affected the definition of hypoxic volume significantly. Using the threshold of abnormal uptake of FMISO, which was determined from the data on normal nasopharyngeal tissue, the dose for the hypoxic region was escalated sufficiently with a lower dose to OAR using New PET compared to using PET/CT, due to the smaller size of GTVh with New PET in an IMRT simulation plan. Development of a more precise and accurate PET scanner can be a breakthrough for accurate dose escalation in FMISO-guided IMRT for patients with NPC. Further investigations are required to confirm our findings. 
